These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 9207469

  • 1. Antisense oligodeoxyribonucleotides suppress hematologic cell growth through stepwise release of deoxyribonucleotides.
    Vaerman JL, Moureau P, Deldime F, Lewalle P, Lammineur C, Morschhauser F, Martiat P.
    Blood; 1997 Jul 01; 90(1):331-9. PubMed ID: 9207469
    [Abstract] [Full Text] [Related]

  • 2. BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism.
    Vaerman JL, Lammineur C, Moureau P, Lewalle P, Deldime F, Blumenfeld M, Martiat P.
    Blood; 1995 Nov 15; 86(10):3891-6. PubMed ID: 7579358
    [Abstract] [Full Text] [Related]

  • 3. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
    Wu AG, Joshi SS, Chan WC, Iversen PL, Jackson JD, Kessinger A, Pirruccello SJ, Sanger WG, Sharp JG, Verbik DJ.
    Leuk Lymphoma; 1995 Dec 15; 20(1-2):67-76. PubMed ID: 8750625
    [Abstract] [Full Text] [Related]

  • 4. Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells.
    de Fabritiis P, Skorski T, De Propris MS, Paggi MG, Nieborowska-Skorska M, Lisci A, Buffolino S, Campbell K, Geiser T, Calabretta B.
    Leukemia; 1997 Jun 15; 11(6):811-9. PubMed ID: 9177433
    [Abstract] [Full Text] [Related]

  • 5. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice.
    Skorski T, Nieborowska-Skorska M, Wlodarski P, Zon G, Iozzo RV, Calabretta B.
    Blood; 1996 Aug 01; 88(3):1005-12. PubMed ID: 8704208
    [Abstract] [Full Text] [Related]

  • 6. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
    Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Hoser G, Kawiak J, Majewski M, Christensen L, Iozzo RV, Calabretta B.
    J Natl Cancer Inst; 1997 Jan 15; 89(2):124-33. PubMed ID: 8998181
    [Abstract] [Full Text] [Related]

  • 7. Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells.
    Broaddus WC, Chen ZJ, Prabhu SS, Loudon WG, Gillies GT, Phillips LL, Fillmore H.
    Neurosurgery; 1997 Oct 15; 41(4):908-15. PubMed ID: 9316053
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA.
    Giles RV, Spiller DG, Green JA, Clark RE, Tidd DM.
    Blood; 1995 Jul 15; 86(2):744-54. PubMed ID: 7606003
    [Abstract] [Full Text] [Related]

  • 12. Retrovirally transduced antisense sequences stably suppress P210BCR-ABL expression and inhibit the proliferation of BCR/ABL-containing cell lines.
    Martiat P, Lewalle P, Taj AS, Philippe M, Larondelle Y, Vaerman JL, Wildmann C, Goldman JM, Michaux JL.
    Blood; 1993 Jan 15; 81(2):502-9. PubMed ID: 8422466
    [Abstract] [Full Text] [Related]

  • 13. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.
    Smetsers TF, Skorski T, van de Locht LT, Wessels HM, Pennings AH, de Witte T, Calabretta B, Mensink EJ.
    Leukemia; 1994 Jan 15; 8(1):129-40. PubMed ID: 8289478
    [Abstract] [Full Text] [Related]

  • 14. The influence of phosphorothioate oligodeoxynucleotides on various organs in vivo.
    Nieborowska-Skórska M, Białek AP, Nicolaides NC, Iozzo RV, Kawalec M, Calabretta B, Kawiak J, Marlicz K, Skórski T.
    Folia Histochem Cytobiol; 1996 Jan 15; 34(2):69-73. PubMed ID: 8875213
    [Abstract] [Full Text] [Related]

  • 15. Capping of bcr-abl antisense oligonucleotides enhances antiproliferative activity against chronic myeloid leukemia cell lines.
    Thomas M, Kosciolek B, Wang N, Rowley P.
    Leuk Res; 1994 Jun 15; 18(6):401-8. PubMed ID: 8207957
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Myeloablative treatment supported by autologous stem cell infusion with neuroblastoma.
    Ryu KH, Seoh JY, Jang PS, Kim CW, Koh SH, Shin HY, Ahn HS.
    J Korean Med Sci; 2003 Apr 15; 18(2):184-90. PubMed ID: 12692414
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
    Mahon FX, Ripoche J, Pigeonnier V, Jazwiec B, Pigneux A, Moreau JF, Reiffers J.
    Exp Hematol; 1995 Dec 15; 23(14):1606-11. PubMed ID: 8542954
    [Abstract] [Full Text] [Related]

  • 20. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.
    Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G, Gewirtz AM, Perussia B, Calabretta B.
    Blood; 1995 Jul 15; 86(2):726-36. PubMed ID: 7606002
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.